INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA

被引：0
|
作者：
Cooper, Nichola [1 ]
Jansen, A. J. Gerard [2 ]
Mayer, Jiri [3 ]
Tarantino, Michael D. [4 ]
Diab, Remco [5 ]
Ward, Brad [6 ]
Daak, Ahmed [6 ]
Kuter, David J. [7 ]
机构：
[1] Hammersmith Hosp, London, England
[2] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands
[3] Masaryk Univ Hosp, Brno, Czech Republic
[4] Univ Illinois, Bleeding & Clotting Disorders Inst, Coll Med Peoria, Peoria, IL USA
[5] Sanofi, Rotkreuz LU, Vernier, Switzerland
[6] Sanofi, Cambridge, MA USA
[7] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [41] Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
    Song, Yuqin
    Zhou, Keshu
    Zou, Dehui
    Zhou, Jianfeng
    Hu, Jianda
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Jin, Jie
    Lv, Fangfang
    Feng, Ru
    Gao, Sujun
    Zhou, Daobin
    Guo, Haiyi
    Wang, Aihua
    Hilger, James
    Huang, Jane
    Novotny, William
    Osman, Muhtar
    Zhu, Jun
    BLOOD, 2018, 132
  • [42] An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies
    Tam, Constantine S.
    Cull, Gavin
    Opat, Stephen
    Gregory, Gareth P.
    Liu, Aichun
    Johnston, Anna M.
    Zhao, Weili
    Roncolato, Fernando
    Handunnetti, Sasanka M.
    Prince, H. Miles
    Yannakou, Costas K.
    Li, Wenyu
    Shih, Ted
    Zhang, Xiaoping
    Wu, Ken
    Liu, Yuan
    Huang, Jane
    Trotman, Judith
    BLOOD, 2019, 134
  • [43] DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study
    Huntington, Scott F.
    Schuster, Stephen J.
    Ding, Wei
    Koehler, Amber B.
    Brander, Danielle M.
    Rosenthal, Allison C.
    Leis, Jose F.
    Tun, Han W.
    Moustafa, Muhamad Alhaj
    Iqbal, Madiha
    He, Wei
    Kearney, Albert S.
    McKinlay, Timothy P.
    Gui, Min
    Mato, Anthony R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (05) : 739 - 749
  • [44] Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies
    Searle, Emma
    Forconi, Francesco
    Linton, Kim
    Danilov, Alexey
    Mckay, Pam
    Lewis, David
    El-Sharkawi, Dima
    Gleeson, Mary
    Riches, John
    Injac, Sarah G.
    Shih, Ted
    Nandakumar, Srinand
    Tan, May
    Cherala, Ganesh
    Meredith, Erin
    Collins, Graham P.
    BLOOD, 2023, 142
  • [45] SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL
    Mease, P. J.
    Deodhar, A.
    Van der Heijde, D.
    Behrens, F.
    Kivitz, A.
    Neal, J.
    Nys, M.
    Lehman, T.
    Delev, N.
    Korish, S.
    Nowak, M.
    Banerjee, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 842 - 843
  • [46] Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
    Mease, Philip J.
    Deodhar, Atul
    van der Heijde, Desiree
    Behrens, Frank
    Kivitz, Alan
    Neal, Jeffrey
    Nys, Marleen
    Lehman, Tom
    Delev, Nikolay
    Korish, Shimon
    Nowak, Miroslawa
    Banerjee, Subhashis
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3167 - 3168
  • [47] Efficacy and Safety of Eltrombopag in Chinese Patients with Chronic Immune Thrombocytopenia: Stage 2 Results from a Multicenter Phase III Study
    Yang, Renchi
    Liu Xiaofan
    Li, Junmin
    Hou, Ming
    Jie, Jin
    Huang, Meijuan
    Yu, Ziqiang
    Xu, Xiaojun
    Zhang, Xiaohui
    BLOOD, 2018, 132
  • [48] Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study
    Liu, Xiaofan
    Hou, Ming
    Li, Junmin
    Jin, Jie
    Huang, Meijuan
    Yu, Ziqiang
    Xu, Xiaojun
    Zhang, Xiaohui
    Yang, Renchi
    PLATELETS, 2022, 33 (01) : 82 - 88
  • [49] A phase 1 study of biib091, a bruton's tyrosine kinase (btk) inhibitor, in healthy adult participants: preliminary results
    Scaramozza, M.
    Arefayene, M.
    Peng, X.
    Palte, M.
    Kam, J.
    Graham, A.
    Riester, K.
    Coppell, A.
    Bame, E.
    Mingueneau, M.
    Hopkins, B.
    Belachew, S.
    Franchimont, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 207 - 207
  • [50] Design of a phase II dose range finding, efficacy and safety study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients
    Montalban, X.
    Bojanowski, J.
    Martin, E.
    Willmer, J.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 324 - 324
12345